Locations:
Search
FDA approval may come in 2019
Lower toxicity than conventional chemo
Groundbreaking study paves way for targeted therapy
Gene signatures differentiate clinical response
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
10-year outcomes favor autologous over implant
Initial study results are encouraging
Higher doses don’t mean higher toxicity
New system better predicts patient outcomes
Second (or third) time’s a charm in reducing splenomegaly and other symptoms
Using data science to identify intrinsic patterns in cancer data
Advertisement
Advertisement